PL2780003T3 - Leczenie niedoczynności kory nadnerczy - Google Patents

Leczenie niedoczynności kory nadnerczy

Info

Publication number
PL2780003T3
PL2780003T3 PL12806617T PL12806617T PL2780003T3 PL 2780003 T3 PL2780003 T3 PL 2780003T3 PL 12806617 T PL12806617 T PL 12806617T PL 12806617 T PL12806617 T PL 12806617T PL 2780003 T3 PL2780003 T3 PL 2780003T3
Authority
PL
Poland
Prior art keywords
hyperrasive
cortex
treatment
hyperrasive cortex
Prior art date
Application number
PL12806617T
Other languages
English (en)
Inventor
Hiep Huatan
Richard Ross
Martin Whitaker
Original Assignee
Diurnal Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Limited filed Critical Diurnal Limited
Publication of PL2780003T3 publication Critical patent/PL2780003T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL12806617T 2011-11-19 2012-11-19 Leczenie niedoczynności kory nadnerczy PL2780003T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1119985.8A GB201119985D0 (en) 2011-11-19 2011-11-19 Treatment of adrenal insufficiency
PCT/GB2012/052864 WO2013072707A1 (en) 2011-11-19 2012-11-19 Treatment of adrenal insufficiency
EP12806617.2A EP2780003B1 (en) 2011-11-19 2012-11-19 Treatment of adrenal insufficiency

Publications (1)

Publication Number Publication Date
PL2780003T3 true PL2780003T3 (pl) 2020-06-29

Family

ID=45475414

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12806617T PL2780003T3 (pl) 2011-11-19 2012-11-19 Leczenie niedoczynności kory nadnerczy

Country Status (22)

Country Link
US (2) US9675559B2 (pl)
EP (1) EP2780003B1 (pl)
JP (2) JP6228125B2 (pl)
KR (1) KR101995999B1 (pl)
AU (1) AU2012338583B2 (pl)
BR (1) BR112014011745B1 (pl)
CA (1) CA2854717C (pl)
CY (1) CY1123130T1 (pl)
DK (1) DK2780003T3 (pl)
ES (1) ES2782503T3 (pl)
GB (2) GB201119985D0 (pl)
HR (1) HRP20200452T1 (pl)
HU (1) HUE048445T2 (pl)
IL (1) IL232065A (pl)
LT (1) LT2780003T (pl)
PL (1) PL2780003T3 (pl)
PT (1) PT2780003T (pl)
RS (1) RS60132B1 (pl)
SI (1) SI2780003T1 (pl)
SM (1) SMT202000230T1 (pl)
WO (1) WO2013072707A1 (pl)
ZA (1) ZA201403462B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
WO2019221483A1 (ko) 2018-05-14 2019-11-21 주식회사 엘지화학 화합물 및 이를 포함하는 유기 발광 소자
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062634T3 (es) * 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
HUP0002744A3 (en) * 1997-01-06 2001-01-29 Pfizer Rapidly releasing and taste-masking pharmaceutical dosage form
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
JP2007533697A (ja) 2004-04-22 2007-11-22 デュオコート エービー グルココルチコイド救急治療用の医薬組成物
RU2382637C2 (ru) 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
US20070281007A1 (en) 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
WO2008126076A2 (en) 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
US8298585B2 (en) * 2007-06-06 2012-10-30 Asahi Kasei Chemicals Corporation Cellulose-based fine core particle and process for producing the same
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
NZ595428A (en) 2009-04-07 2013-04-26 Duocourt Pharma Ab Improved glucocorticoid therapy
JP5758899B2 (ja) * 2009-09-17 2015-08-05 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 活性物質を含有するコーティングにより被覆されたペレット
BR112012029466A2 (pt) 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Also Published As

Publication number Publication date
LT2780003T (lt) 2020-04-27
AU2012338583B2 (en) 2017-01-19
BR112014011745B1 (pt) 2022-04-05
WO2013072707A1 (en) 2013-05-23
GB2509663B (en) 2015-01-07
GB201119985D0 (en) 2012-01-04
US9675559B2 (en) 2017-06-13
AU2012338583A1 (en) 2014-05-01
IL232065A0 (en) 2014-05-28
GB201407380D0 (en) 2014-06-11
BR112014011745A2 (pt) 2017-05-30
JP2017200942A (ja) 2017-11-09
SMT202000230T1 (it) 2020-07-08
US20170202856A1 (en) 2017-07-20
KR20140108638A (ko) 2014-09-12
DK2780003T3 (da) 2020-03-30
US20140287052A1 (en) 2014-09-25
SI2780003T1 (sl) 2020-07-31
GB2509663A (en) 2014-07-09
EP2780003B1 (en) 2020-02-19
ZA201403462B (en) 2016-05-25
RS60132B1 (sr) 2020-05-29
CY1123130T1 (el) 2021-10-29
KR101995999B1 (ko) 2019-07-03
CA2854717C (en) 2020-12-08
JP6228125B2 (ja) 2017-11-08
HUE048445T2 (hu) 2020-08-28
IL232065A (en) 2016-04-21
HK1194005A1 (en) 2014-10-10
JP2014533679A (ja) 2014-12-15
EP2780003A1 (en) 2014-09-24
US9717740B1 (en) 2017-08-01
ES2782503T3 (es) 2020-09-15
CA2854717A1 (en) 2013-05-23
HRP20200452T1 (hr) 2020-10-16
PT2780003T (pt) 2020-04-08

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
LT2885010T (lt) Tautopatijos gydymo būdai
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
PT2766014T (pt) Métodos de tratar pacientes pediátricos utilizando dexmedetomidina
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
EP2740419A4 (en) TREATMENT INSTRUMENT
EP2819703A4 (en) PAIN TREATMENT
HUE053247T2 (hu) Mieloszuppresszió kezelése
PL3251666T3 (pl) Sposób leczenia urazu neurologicznego
SMT201600129B (it) Trattamento della lipodistrofia
HRP20180237T1 (hr) Metode za liječenje hcv-a
DK2717941T3 (da) Behandling af cancer
EP2906208A4 (en) THERAPEUTIC TREATMENT
BR112014007029A2 (pt) métodos aperfeiçoados de terapia gênica
IL231092A0 (en) Treatment of rhinitis
EP2750709A4 (en) TREATMENT OF KACHEXIE
BR112013022820A2 (pt) método de tratamento
PL2776055T3 (pl) Sposoby leczenia zaburzeń żołądkowo-jelitowych
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
BR112013023142A2 (pt) método de tratamento de cabelos
EP2709665A4 (en) TREATMENT OF PSORIASIS
HRP20181000T1 (hr) Postupci liječenja stanja povezanih s kosom
PL3536410T3 (pl) Metoda przetwarzania odpadów